AZN - Week In Review: OrbiMed Raises $800 Million For Its Fourth Asia Fund
- The Asia Partners series of funds invests primarily in China and India, from venture capital through growth stage for biotech, pharma, medical device, diagnostic and healthcare companies.
- WuXi AppTec, a China-global CRO/CMO, paid $135 million to acquire Oxgene, a UK CDMO that develops scaleable gene technologies to develop cell and gene therapies.
- Shangai's Junshi Bio out-licensed certain China marketing rights for its approved PD-1 to AstraZeneca.
- In 2020, Apollomics acquired China rights to uproleselan from GlycoMimetics in a two-drug, $189 million deal.
For further details see:
Week In Review: OrbiMed Raises $800 Million For Its Fourth Asia Fund